212Pb {alpha}-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study

Conclusion: These results showed 212Pb-daratumumab to have efficacy in xenografted mice, with significant tumor regression and increased survival. This study highlights the potency of α-RIT in MM treatment.

Source: Journal of Nuclear Medicine - June 30, 2020 Category: Nuclear Medicine Authors: Quelven, I., Monteil, J., Sage, M., Saidi, A., Mounier, J., Bayout, A., Garrier, J., Cogne, M., Durand-Panteix, S. Tags: Basic Source Type: research